| Document |
Document Title |
|
JP2022501445A |
The present invention discloses a terpenoid derivative as an NRF2 inhibitor and a pharmaceutical composition containing the compound. The title compounds and compositions are useful in the treatment of inflammatory diseases. [Selection d...
|
|
JP6900385B2 |
The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and ...
|
|
JP2021512909A |
The present invention relates to a steroidal derivative modulator, a method for producing the same, and an application thereof. The present invention particularly relates to a compound represented by the general formula (I), a method for...
|
|
JP2021506904A |
Equation (II) [Chemical 593]Compounds or pharmaceutically acceptable salts thereof are provided herein and in formula (II), R.7, R3, R9, R6a, R6b, R11a, R11b, R15a, R15b, R16a, R16b, R17a, R17b, R18a, R18b, R19a, R19b, R5a, R5b, R8, And ...
|
|
JP6822135B2 |
Provided is a method for synthesizing high-purity glycyrrhizic acid or galacturo glycyrrhizic acid in a simple and high-yield manner. A production method is characterized by glycosylating a hydroxyl group at position 3 of the glycyrrhizi...
|
|
JP2020533377A |
The present invention provides diethanolamine ursolic acid salt and morpholine salt. Compositions containing the salt and methods of using the salt are also provided.
|
|
JP6786410B2 |
The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin ...
|
|
JP6779494B2 |
To provide a novel triterpene, a method for producing the same and a composition containing the same.The present invention provides a triterpene represented by formula (I) [where Ris a hydrogen atom or a methyl group, and Ris a hydrogen ...
|
|
JP6770596B2 |
The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin ...
|
|
JP2020526536A |
The present invention relates to novel uses of saponins containing an acetyl residue as one of their sugar residues. These saponins can enhance transfection efficiency to surprisingly high levels over known saponins and even more than li...
|
|
JP6735837B2 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhib...
|
|
JP6643951B2 |
To provide triterpenoid extraction methods that can suppress the amount of organic solvent used as much as possible, and to provide methods of separating triterpenoid and carotenoid easily.Provided are a triterpenoid extraction method co...
|
|
JP6644433B2 |
The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical ...
|
|
JP6637136B2 |
The present invention relates to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,1
2a-heptamethyl-10,14-dioxo-l,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,
12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropana
mide an...
|
|
JP6620149B2 |
These compounds are useful for the treatment of HIV and AIDS.
|
|
JP6606636B2 |
|
|
JP6598224B2 |
Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein R=-C(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1α and HIF-2α proteins...
|
|
JP6568202B2 |
Combinations of a compound according to formula Ia and an AIDS antiviral, immunomodulator, HIV entry inhibitor, anti-infective or vaccine. These combinations can be used in the treatment of HIV.
|
|
JP2019523245A |
The present invention provides for the use of compounds of formula I as ligands for orphan nuclear receptors and in the prevention or treatment of diseases associated with orphan nuclear receptors. [Chemical 118]
|
|
JP6549544B2 |
This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, l...
|
|
JP2019513770A |
The present invention provides a conjugate comprising a targeting moiety, a nucleic acid, and any linking group, as well as synthetic intermediates and methods useful for preparing the conjugate. This conjugate guides therapeutic nucleic...
|
|
JP2019068741A |
To provide algae that produce sterol, and a method for producing sterol using the same.Algae such as AJ7867 strain (FERM P-22304) and a strain derived therefrom, having a sterol production ability, are cultured. From bodies of the result...
|
|
JP2019052105A |
To provide a novel compound having anti-HIV activity.The present invention provides a compound illustrated by the formula B or a salt thereof.SELECTED DRAWING: None
|
|
JP2019048867A |
To provide a cardiogenin major-isomer that is substantially free of the minor isomer (called "isolated cardiogenin major isomer").An isolated cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated fr...
|
|
JP2019023200A |
To provide crystalline polymorphic forms of 2,2-difluoropropionamide derivatives of bardoxolone methyl, methods for preparation and use thereof, and pharmaceutical compositions containing the same.There is provided a polymorphic form of ...
|
|
JP2019502728A |
The present invention relates to a compound characterized by having a structure according to the following formula (I), or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful in the treatment or ...
|
|
JP6441807B2 |
The present invention relates to the use of triterpenoid derivatives for the preparation of a medicament for preventing or treating influenza diseases, in which the substituents are as defined in the specification. The triterpenoid deriv...
|
|
JP6410710B2 |
The present invention relates to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,1
2a-heptamethyl-10,14-dioxo-l,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,
12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropana
mide an...
|
|
JP6409050B2 |
The present invention relates generally to the compound: N -((4a S ,6a R ,6b S ,8a R ,12a S ,14a R ,14b S )-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4
,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-
4a-yl)-2,...
|
|
JP2018528231A |
The present invention relates to a compound having a structure according to the following formula (I), or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful for the treatment or prevention of HIV.
|
|
JP2018523651A |
The process for extracting and concentrating saponins from agricultural raw materials. Agricultural feedstock can undergo a first preparation step aimed at increasing the surface area of the feedstock in order to increase the efficiency ...
|
|
JP2018521107A |
The present invention relates to a compound having a structure according to the following formula (I), or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful in the treatment or prevention of HIV...
|
|
JP2018521093A |
The present invention relates to a compound having a structure according to the following formula (I), or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful in the treatment or prevention of HIV...
|
|
JP6359561B2 |
The present invention provides saponin adjuvants, which are useful in vaccines against carbohydrate antigens.
|
|
JP6360830B2 |
The present disclosure concerns methods for producing purified saponins, such as QS-21, which reduces the number of necessary lyophilization cycles to one by a step of solvent exchange and optional subsequent exposure of the purified sap...
|
|
JP6328102B2 |
It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway. The present invention provides terpenoid derivative A represent...
|
|
JP2018512433A |
A method for producing an HIV maturation inhibitor compound using bethulin chemical structure (I) as a starting material and using the Lossen rearrangement technique is shown. [Selection diagram] None
|
|
JP2018065867A |
To discover alternative compounds that are an effective balance of properties for the prevention and/or treatment of HIV infections.The present invention relates to a compound having the structure of Formula I, or a pharmaceutically acce...
|
|
JP6300730B2 |
The present invention relates to compounds characterized by having a structure according to the following Formula I: , or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prev...
|
|
JP6289659B2 |
The present invention relates to new pentacyclic triterpenes, their preparation method and use. The compounds of the present invention could effectively treat psoriasis and selectively inhibit in vitro differentiation of the T H 1 and T ...
|
|
JP6272870B2 |
Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising...
|
|
JP2018009001A |
To provide more effective triterpenoid analogs since the naturally occurring triterpenoids which are biosynthesized in plants by the cyclization of squalene display relatively weak biological activity, although they are candidates for me...
|
|
JP6243428B2 |
wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the comp...
|
|
JP2017533934A |
Compounds having properties that affect drugs and living organisms, their pharmaceutical compositions and methods of use are described. In particular, a betulinic acid derivative having a unique antiviral activity, represented as a compo...
|
|
JP2017533937A |
Compounds having properties that affect drugs and living organisms, their pharmaceutical compositions and methods of use are described. In particular, betulinic acid derivatives with unique antiviral activity, represented as compounds of...
|
|
JP6227665B2 |
Disclosed is a novel glycyrrhetinic acid derivative. The glycyrrhetinic acid derivative is represented by the following general formula (1).
|
|
JP6225103B2 |
An organocatalyst for oxidizing alcohols in which a primary alcohol is selectively oxidized in a polyol substrate having a plurality of alcohols under environmentally-friendly conditions. The organic oxidation catalyst has an oxygen atom...
|
|
JP6211527B2 |
The present invention belongs to the field of natural medicine and pharmaceutical chemistry, and specifically relates to novel 2-substituted oleanolic acid derivatives of formula (I) or a pharmaceutically acceptable salt thereof, to a pr...
|
|
JP6212545B2 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 bicyclic amines of triterpenoids that possess unique antiviral activity are provided as HIV matur...
|
|
JP6186012B2 |
Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, alkyl and alkenyl C-3 modified betulinic acid derivatives that possess unique antiviral activity are p...
|
